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A B S T R A C T
Background: Studies have shown the safety of home treatment of patients with pulmonary embolism (PE) at low
risk of adverse events. Management studies focusing on home treatment have suggested that 30% to 55% of
acute PE patients could be treated at home, based on the HESTIA criteria, but data from day-to-day clinical
practice are largely unavailable.
Aim: To determine current practice patterns of home treatment of acute PE in the Netherlands.
Method: We performed a post-hoc analysis of the YEARS study. The main outcomes were the proportion of
patients who were discharged< 24 h and reasons for admission if treated in hospital. Further, we compared the
3-month incidence of PE-related unscheduled readmissions between patients treated at home and in hospital.
Results: Of the 404 outpatients with PE included in this post-hoc analysis of the YEARS study, 184 (46%) were
treated at home. The median duration of admission of the hospitalized patients was 3.0 days. The rate of PE-
related readmissions of patients treated at home was 9.7% versus 8.6% for hospitalized patients (crude hazard
ratio 1.1 (95% CI 0.57–2.1)). The 3-month incidence of any adverse event was 3.8% in those treated at home (2
recurrent VTE, 3 major bleedings and two deaths) compared to 10% in the hospitalized patients (3 recurrent
VTE, 6 major bleedings and fourteen deaths).
Conclusions: In the YEARS study, 46% of patients with PE were treated at home with low incidence of adverse
events. PE-related readmission rates were not different between patients treated at home or in hospital.
1. Introduction
Over the last decade, there has been a trend towards treating pa-
tients with pulmonary embolism (PE) at low-risk of early adverse events
at home. The safety and feasibility of home treatment in selected pa-
tients with PE has already been shown in several large trials, although
the optimal method for selecting relevant patients is still debated
[1–10]. The severity of the PE and risk of adverse outcomes largely
determine clinical decision making with regard to initial home treat-
ment. Other factors such as locoregional cultural and patient pre-
ferences, the (financing of the) healthcare system and corresponding
infrastructure also play a role. These latter greatly differ between
https://doi.org/10.1016/j.thromres.2020.05.038
Received 26 March 2020; Received in revised form 30 April 2020; Accepted 25 May 2020
⁎ Corresponding author at: Department of Thrombosis and Haemostasis, Leiden University Medical Centre, Albinusdreef 2, 2300 RC Leiden, the Netherlands.
E-mail address: s.v.hendriks@lumc.nl (S.V. Hendriks).
Thrombosis Research 193 (2020) 60–65
Available online 30 May 2020
0049-3848/ © 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license 
(http://creativecommons.org/licenses/BY/4.0/).
T
countries, as was recently demonstrated in a post-hoc analysis of the
Hokusai VTE study: the vast majority of Canadian patients was treated
at home in contrast to only a quarter of the patients from the United
States [11]. Same differences were observed between countries in
Europe, as more than half of all patients were treated at home in Ger-
many and the United Kingdom, whereas the majority of patients in
Spain or France were initially hospitalized.
It has been suggested that as much as 30% to 55% of patients with
acute PE could be selected for home treatment [10,12,13]. These
numbers were found in prospective outcome studies focusing on home
treatment, but detailed data from day-to-day clinical practice is cur-
rently largely unavailable. We therefore aimed to evaluate current
practice patterns and outcome of home treatment of patients with
confirmed PE in Dutch Hospitals.
2. Methods
2.1. Design
The current study was a post-hoc analysis of the YEARS study. The
YEARS study was a prospective, multicenter, diagnostic management
study conducted in 12 university or community hospitals in the
Netherlands between October 2013 and July 2015 in patients with
suspected acute PE. The YEARS study aimed to validate the diagnostic
YEARS algorithm, consisting of three Wells criteria (clinical signs of
deep vein thrombosis, haemoptysis, and assessment whether PE is the
most likely diagnosis) with simultaneous assessment of the D-dimer
concentrations [14]. According to the algorithm, PE is excluded in
patients without YEARS items and D-dimer < 1000 ng/mL, or in pa-
tients with one or more YEARS items and D-dimer < 500 ng/mL.
Patients were eligible for inclusion if they were aged 18 years or older,
with the main exclusion criteria of initiated therapeutic doses of an-
ticoagulants 24 h or more before eligibility assessment. Furthermore, a
life expectancy<3 months, an expected inability to achieve the re-
quired 3-month follow-up, pregnancy and allergy to intravenous con-
trast agent were exclusion criteria. Patients were followed for three
months to assess the occurrence of symptomatic venous thromboem-
bolism (VTE).
For the present analysis, all outpatients who were diagnosed with
acute PE at baseline were eligible for inclusion. Eleven of 12 hospitals
were able to provide additional data. In the participating hospitals,
decision for hospitalization or home treatment was mainly based on the
Hestia criteria. However this was not part of the study protocol and was
left to the discretion of the treating physician. The Hestia rule contains
eleven pragmatic parameters to select PE patients who do not require
in-hospital care (Appendix) [10].
2.2. Study objectives
The primary aim of this study was to determine current patterns of
home treatment in patients with confirmed acute PE in the Netherlands,
i.e. the proportion of patients with symptomatic PE who were treated at
home, defined as discharged from the hospital within 24 h after diag-
nosis. Furthermore, reasons for admission if treated in hospital were
evaluated.
The secondary aims were 1) to evaluate the 3-month incidence of
unscheduled PE-related readmissions in both home treated or hospita-
lized patients and 2) to evaluate the duration of hospitalization if
treatment started initially in hospital, i.e. the median duration of ad-
mission; and 3) to compare the clinical outcome of PE patients treated
at home or in hospital. This latter endpoint includes all-cause mortality,
recurrent VTE and major bleeding during a 3-month follow-up period.
2.3. Study definitions
Acute PE was defined as an intraluminal filling defects of the
subsegmental or more proximal pulmonary arteries confirmed by
computed tomographic pulmonary angiography (CTPA). Recurrent VTE
was defined as a new intraluminal filling defect on CTPA or con-
firmation of a new PE at autopsy. Recurrent lower extremity DVT was
defined as new non-compressibility by ultrasonography or as an in-
crease in vein diameter under maximal compression, as measured in the
abnormal venous segment, indicating an increase in thrombus diameter
(≥4 mm) or by a positive signal on magnetic resonance direct
thrombus imaging (MRDTI) indicative of fresh thrombus in the prox-
imal veins of the leg [15].
Major bleeding was defined as any bleeding resulting in death;
symptomatic bleeding in a critical organ (intracranial, intra spinal, in-
traocular, retroperitoneal, intra articular and pericardial bleeding and
muscle bleeding resulting in compartment syndrome) or symptomatic
bleeding resulting in a decrease in the hemoglobin concentration of at
least 2 g/dL or resulting in the transfusion of at least two packs of red
blood cells, following the ISTH criteria [16].
In case of death, information was obtained from the hospital re-
cords. Deaths were classified as caused by PE when confirmed by au-
topsy, shown by objective testing shortly before death, or if it could not
be confidently excluded as a cause of death.
PE-related readmission was defined as any unscheduled visit to the
outpatient clinic, emergency room or readmission in hospital due to PE-
related complications, such as thoracic pain, dyspnea, major bleeding,
clinically relevant non-major bleeding or (suspected) recurrent VTE.
An independent adjudication committee assessed and adjudicated
all (suspected) adverse events occurring during follow-up.
2.4. Statistical analysis
Categorical data are presented as percentages and continuous
variables as means ± standard deviation. The proportion of patients
who were discharged within 24 h after diagnosis and reasons for ad-
mission are provided as frequencies with corresponding 95% con-
fidence intervals (95% CI). Also, frequencies with corresponding 95%
CI will be provided to assess the 3-month incidence of PE-related un-
scheduled readmissions.
In order to describe the natural course of PE in patients treated at
home or hospitalized (secondary outcomes), crude Odds Ratios are
provided with corresponding 95% CI which allows for providing the
relevant perspective. Because patients treated at home or hospitalized
are inherently different (hospitalized patients have a different risk
profile for adverse outcome), we did not perform multivariate analysis
to formally compare the outcomes of the two patient cohorts. The cu-
mulative incidence of PE-related unscheduled readmission according to
initial treatment management was compared with a hazard ratio. SPSS
version 25.0.0 (SPSS, IBM) was used to perform all analyses.
3. Results
3.1. Study patients
A total of 456 patients were diagnosed with acute PE in the YEARS
study. Of these, 52 were excluded for this current analysis because PE
was diagnosed during hospitalization or patients were included in the
one hospital that could not provide additional data for this sub study.
The baseline characteristics of the 404 remaining study patients are
summarized in Table 1. Their mean age was 59 years (standard de-
viation (SD) 16), 52% was female and 13% had active malignancy at
time of diagnosis. Patients initially treated at home were younger with a
mean age of 56 years compared to 62 of those initially hospitalized
(mean difference 6.1 years (95% CI 2.9–9.3)) and had less renal in-
sufficiency, 13% vs 23% (OR 0.49, 95% CI 0.29–0.85). In this cohort,
the majority of patients were treated with vitamin K antagonists while
only 4.2% were treated with direct oral anticoagulants (DOAC).
S.V. Hendriks, et al. Thrombosis Research 193 (2020) 60–65
61
3.2. Primary outcome
Of the 404 patients, 184 (46%, 95% CI 41–50) were treated at home
whereas the remaining 220 patients (54%) were treated in hospital. The
median duration of admission of those initially hospitalized was
3.0 days (interquartile range 2.0–5.0). In 1.7% of patients, the duration
of admission could not be retrieved. Reasons for hospitalization are
shown in Table 2 and consisted mainly of need for oxygen adminis-
tration (37%) and “medical or social reasons” (47%; Table 3). Of note,
relevant inter hospital differences were observed in the proportion of
patients treated initially at home treatment with percentages ranging
from 13% to 83% (Fig. 1).
3.3. Secondary outcome
The 3-month cumulative incidence of any adverse event was 3.8%
(95% confidence interval (CI) 1.5%–7.7%) in those treated at home (2
recurrent VTE, 3 major bleedings and two deaths) versus 10% (95% CI
6.7%–15.3%) in the initially hospitalized patients (3 recurrent VTE, 6
major bleedings and fourteen deaths). Specifications of the adverse
events of patients with PE treated at home are described in Table 4. In
those patients treated at home, none of the major bleeding or recurrent
VTE events were fatal. The two deaths were adjudicated not to be as-
sociated to VTE: one occurred in the setting of progressive non-small
cell lung carcinoma and the other patient died of progressive non-
specified interstitial pneumonia requiring increasing amounts of oxygen
suppletion.
The rate of PE-associated unscheduled readmissions in patients
treated at home was 9.7% versus 8.6% for initially hospitalized pa-
tients, for a crude hazard ratio of 1.1 (95% CI 0.57–2.1; Fig. 2). The
main reason for readmission was thoracic pain (n = 16, 43%). Speci-
fication of all reasons for an unscheduled readmission is provided in
Table 5. The PE-associated unscheduled readmissions of patients in-
itially hospitalized consisted of nine admissions, eight emergency room
visits and two unscheduled visits to the outpatient clinic, whereas un-
scheduled PE-associated readmissions of patients treated at home con-
sisted of nine admissions and nine emergency room visits.
4. Discussion
This post-hoc analysis of the YEARS study showed that 46% of all
outpatients with confirmed PE were treated at home in Dutch daily
clinical practice. The incidence of adverse outcome for those treated at
home was low and PE-associated unscheduled readmission rates were
not different between patients treated at home or initially managed in
hospital.
Although we observed relevant inter hospital differences regarding
the proportion of home treatment with percentages ranging from 13%
to 83%, the overall proportion of patients treated at home in this
analysis is very much in line with numbers suggested in prospective
outcome studies focusing on home treatment. In the Hestia study 297
(51%) of the initially screened 581 patients were treated at home, while
this was 152/351 (43%) and 516/1102 (47%) in two other studies
[3,6,10]. Limited data are available from practice based studies in other
countries. Published literature from three countries showed lower rates
of home treatment, with numbers variating from 10 to 33% [13,17–19].
This 33% was observed in a large Italian prospective cohort comparing
different risk stratification scores [13]. In that study, the Hestia criteria
identified a higher proportion (42%) of PE patients eligible for early
discharge (within 48 h) than the PESI (24%) and sPESI (18%) scores.
Where the introduction of DOACs has likely lowered the threshold
for treating a PE patient at home, it may also lead to a decrease in the
mean duration of hospitalization. The median duration of admission in
the hospitalized patients in our cohort was 3.0 days, with the vast
majority of all patients in this cohort treated with low-molecular weight
heparin followed by vitamin K antagonists. Notably, this was shorter
than found in a large study comprising mainly European hospitals
showing a mean duration of 13.6 days in 2001 and 9.3 days in 2013
[7,20]. This decrease in length of stay was also observed in recent
published data from the United States showing a decrease to 6 days of
hospitalization in 2015 [21]. Notably, the mean duration of admission
Table 1
Baseline characteristics of outpatients with acute pulmonary embolism of the
YEARS study.
Home
treatment
(n = 184)
Initial
hospitalization
(n = 220)
Total
(n = 404)
Age, mean (SD) 56 (16) 62 (16) 59 (16)
Male sex, no (%) 92 (50) 100 (47) 195 (48)
Weight in kg, mean (SD) 85 (17) 86 (19) 86 (18)
Body Mass Index, mean (SD) 28 (5.4) 28 (5.8) 28 (5.6)
Creatinine
clearance < 60 ml/mina —
no. (%)
23 (13) 48 (23) 73 (18)
COPD (%) 7 (3.8) 14 (6.6) 21 (5.2)
Heart failure (%) 2 (1.1) 8 (3.8) 11 (2.7)
Mean duration of symptoms in
days (SD)
8.6 (17) 8.2 (18) 8.3 (17)
Previous VTE — no. (%) 51 (28) 44 (21) 95 (24)
DVT 21 (11) 14 (6.6) 35 (8.7)
PE ± DVT 26 (14) 30 (14) 57 (14)
Estrogen use (%) 25 (14) 19 (8.9) 44 (11)
Active malignancy no. (%) 21 (11) 31 (15) 53 (13)
Abbreviations: PE, pulmonary embolism; SD, standard deviation; VTE, venous
thromboembolism; DVT, Deep vein thrombosis; COPD, chronic obstructive
pulmonary disease.
a Estimated GFR calculated by the abbreviated MDRD equation.
Table 2
Reasons for hospitalization after diagnosis PE.a
Reasons for hospital admission Frequency Proportion
1. Hemodynamically unstable 15 7.0%
2. Need for thrombolysis or embolectomy 1 0.47%
3. Active bleeding or high bleeding risk 10 4.7%
4. > 24 h oxygen supply 78 37%
5. Need for intravenous pain medication > 24 h 21 9.9%
6. Medical or social reasons 100 47%
7. Renal insufficiency (< 30 ml/min) 5 2.3%
8. Severe liver impairment 2 0.94%
9. New PE during anticoagulant treatment 3 1.4%
10 No risk stratification scheme such as Hestia applied 26 12%
Abbreviations: PE, pulmonary embolism.
a Multiple Hestia criteria for admission could be scored in one patient.
Table 3
Reasons for awarding the subjective Hestia criterion ‘social or medical reason
for admission’.
Reasons for hospital admission Frequency Proportion
1. Concomitant infection 16 16
2. Malignancy 9 9
3. Concomitant acute condition, e.g. electrolyte
disorders
14 14
4. Extensive PE 13 13
5. PE related cardiac problems 5 5
6. Outpatient treatment not feasible because of
comorbidities or social reasons
16 16
7. Need for pain medication (not i.v.) 5 5
8. Contrast allergy 1 1
9. Other 21 21
Total 100
Abbreviations: PE, pulmonary embolism; i.v., intravenously, extensive PE:
saddle embolus, large thrombus load, RV dilatation; PE related cardiac pro-
blems: rhythm alterations, syncope.
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in the current study may thus decrease even further with more ex-
tensive use of DOACs than the observed proportion of 4.2%. The main
reasons for in-hospital care were oxygen administration (37%) and
“medical or social reasons” (47%); these frequencies are very compar-
able to those shown in dedicated outpatient management studies
[6,10].
The incidence of adverse events in the patients treated at home was
low. These low adverse event rates were very much comparable to
those observed in the Vesta and Hestia studies, in which patients were
treated at home in the absence of any Hestia criteria [6,10]. This low
rate of events was also found in the HoT-PE trial, in which patients were
selected by the majority of the exclusion criteria correspond to the
items of the Hestia criteria in combination with the mandatory absence
of right ventricular dysfunction [22]. In current literature, data re-
garding unscheduled readmissions in PE patients after initial home
treatment is only sparsely available. To our surprise, we could not de-
monstrate a difference between patients treated at home or in hospital.
Notably, the proportion of patients with a readmission or prolonged
initial hospitalization in the HoT-PE study was 10% as well. Slightly
higher readmission rates (± 15%) were reported in a large retro-
spective cohort study in the United States using international classifi-
cation of diseases (ICD) codes for the identification of PE [21,22].
Strong points of this study include the novelty of our data, the
completeness of follow-up, the multicentric design and the practice
based setting. Main limitation of this study is the post-hoc design. Data
concerning major bleeding and the Hestia criteria was not prospectively
collected in the YEARS study, but were extracted from the medical
charts. Also, as the YEARS study was a management study, under-
representation of high-risk subgroups is possible, including but not
limited to pregnant patients or hemodynamically instable patients.
Even so, as the YEARS algorithm was implemented as standard diag-
nostic strategy in all participating hospitals, the vast majority of all
potential PE patients participated in the original study, underlying the
validity of our conclusions.
In conclusion, 46% of all outpatients with acute PE participating in
the YEARS study were treated at home. Rates of adverse events were
low and PE-related unscheduled readmission rates were not different
between patients treated at home or in hospital. This supports the
widespread trend to treat PE patients more often at home.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.thromres.2020.05.038.
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Fig. 2. Cumulative incidence of PE-related unscheduled readmissions to the hospital.
Table 5
Reasons for readmission.
Home treatment
n (%)
Initial hospitalization
n (%)
Median time until readmission in days
n (IQR)
1. Thoracic pain 8 (4.3) 8 (3.6) 9 (2–34)
2. Dyspnea (without any other explanation than PE) 2 (1.0) 3 (1.4) 7 (7–68)
3. Major bleeding 2 (1.0) 3 (1.4) 12 (8–39)
4. Clinically relevant non-major bleeding 3 (1.6) 4 (1.8) 25 (23–62)
5. Recurrent VTE 2 (1.0) 1 (0.5) 26 (14–34)
6. Total 18 (9.7) 19 (8.6) 29 (13–84)
Abbreviations: IQR interquartile range; PE, pulmonary embolism; VTE, venous thromboembolism.
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